Table 2 Patient characteristics and treatment details.
Tumour number | Age (years) | Metastatic disease | Molecular status | Prior surgery (breast) | Prior RT to breast | Systemic therapy before three months of MR | Targeted tumour volume (MRgFUS-MB) | RT volume | Number of cells | FUS power | Systemic therapy after MRgFUS-MB |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 72 | Bone, liver | TNBC | BCS | None | None | 24 cc | Partial breast | 3 | 4 Watts | Capecitabine |
2L | 75 | Pleural effusion | ER + PR + HER2- | BCS | 26 years back (details NA) | Palbociclib, Letrozole | 5 cc | Partial breast | 3 | 7 Watts | Palbociclib, Letrozole |
2R | 75 | Pleural effusion | ER + PR + HER2- | BCS | 26 years back (details NA) | Palbociclib, Letrozole | 5 cc | Partial breast | 3 | 4 Watts | Palbociclib, Letrozole |
3 | 59 | Neck nodes, bone, liver | ER-PR-HER2 + | Mastectomy | None | Trastuzumab emtansine, Capecitabine | 19 cc | Partial breast | 4 | 6 Watts | Trastuzumab emtansine, Capecitabine |
4 | 44 | None | TNBC | BCS | 50 Gy/25fractions (2 years back) | None | 36 cc | Whole breast | 6 | 4 Watts | Capecitabine |
5 | 59 | Neck nodes, bone, lung | ER + PR + HER2- | None | None | None | 10 cc | Partial breast | 3 | 8 Watts | Fulvestrant, capecitabine |
6 | 76 | Lung | ER + PR + HER2- | BCS | 50 Gy/25 fractions (35 years back) | Capecitabine | 32 cc | Partial breast | 5 | 5 Watts | Tamoxifen, Olaparib |
7 | 57 | Lungs, pleural effusion, retroperitoneal nodes | ER + PR-HER2 + | None | None | Trastuzumab | 29 cc (skin nodules over medial aspect) | Whole breast | 7 | 4 Watts | Nab-paclitaxel, neratinib, capecitabine, trastuzumab |
8 | 61 | Lung | TNBC | Mastectomy | 50 Gy/25 fractions (1 year back) | Gemcitabine, Carboplatin, Atezolizumab | 76 cc (skin nodules over the medial aspect of scar and chest wall) | Whole breast | 8 | 4 Watts | Gemcitabine, Carboplatin, Atezolizumab |
